Probably huh? I’ll defer to you since I have no doubt you put a lot of research into that claim before coming out swinging.
So, according to you, Norditropin only uses anti-aggregation ingredients because it comes in liquid form, not because it’s a high concentration rHGH (36iu /ml). Genotropin, which is the same high concentration, comes as lyophilized powder, just like our UGL vials. It’s not reconstituted until right before use, so Genos won’t need anti-aggregation ingredients, because that’s not a real concern, and I “intentionally ignored Genotropin” because it wouldn’t support my claim that pharma doesn’t go higher than 15iu/ml with normal rHGH formulas, to avoid aggregation, and neither should we.
Let’s have a look.
View attachment 362099
“Glycine”?
Let’s hit the biopharma textbooks together and see if we can figure out why Pfizer put that in a lyophilized rHGH powder.
We’ll start with the classic protein drug excipient ingredient chart:
View attachment 362101
Hmm, maybe that’s a mistake. Aggregation of rHGH can’t be a real problem since you “probably” reconstitute 40iu with 1ml all the time and it’s “perfectly clear”, which is why you’re so bent out of shape that I’m suggesting that’s not a good idea. We better double check.
View attachment 362102
Nope, looks like it’s there to prevent aggregation.
I should probably stop before I tell you more things you don’t want to hear. Like how that “clear” 36iu vial reconstituted in a couple drops of Amazon’s cheapest tap water and rubbing alcohol “reconstitution solution”, unfiltered, and filled with a massive amount of sub-visible aggregates acts like a rHGH “vaccine”, increasing the number of antibodies that neutralize rHGH with every injection, so it slowly becomes less effective over time. “Immunogenicity”. An immunity against rHGH that once built, can take years to, or may never, go away.
Not that that’s real enough rHGH brands advertise that they have lower antibody rates vs competitors or anything….
View attachment 362105View attachment 362106
“RIA” is is the level of rHGH antibodies
“Inhibition” is loss of rHGH effectiveness
View attachment 362107
When response to rHGH weakens from high antibodies, they try taking a break or changing brands. Since rHGH molecules are the same, the only real difference between brands likely to explain why a brand change might reduce immune response is because some formulations have fewer aggregates than others. Since aggregates form AFTER reconstitution, the main difference has to be that some formulas do a better job of preventing aggregation.
Or just don’t worry about all this. Follow pharma’s lead, and reconstitute UGL rHGH with the same 15iu/ml limit as pharma does. Maybe even filter to reduce aggregates further so the risk of immunogenicity (and many other long term hazards from contaminants) can be avoided.
View attachment 362110
.